Human leukocyte antigen matching in renal transplantation: review and current status

Role of HLA compatibility in pediatric living-related liver transplantation

BACKGROUND

Human leukocyte antigen (HLA) matching is, at present, not used for the allocation of cadaveric hepatic allografts because the liver is generally believed to be less susceptible to HLA-mediated rejection. However, the exact role of HLA compatibility in the long-term outcome of liver transplantation is not yet clearly defined. One of the advantages of living-related liver transplantation (LRLT) could be a better histocompatibility between donor and recipient. This study aimed at an assessment of the influence of HLA compatibility in a large series of LRLTs.

METHODS

A total of 321 pediatric patients who underwent ABO-identical or ABO-compatible primary LRLT from the parental donors in the period between June 1990 and August 2000 were involved in the study. Graft survival, rejection episodes, and immunosuppression were evaluated from the viewpoint of HLA compatibility.

RESULTS

The overall 1- and 5-year graft survivals were 85.7% and 84.1%, respectively. The cumulative 5-year graft survivals in HLA 0-, 1-, 2- and 3-mismatch groups (A, B, and DR) were 100% (n=10), 78.9% (n=19), 86.2% (n=87), and 82.9% (n=205), respectively (P=0.525). The overall incidence of rejection during the follow-up period (median 66 months, range 16-139 months) was 46.1%. No significant difference was found in the incidence of rejection and rejection-free survival among the four groups. However, steroid-resistant rejection that necessitated OKT3 treatment (n=6) and chronic rejection (n=2) were recognized only in the 3-mismatch group. The whole-blood trough level of tacrolimus and the duration of steroid administration were not significantly different among the groups. The rate of the patients who succeeded in withdrawal from immunosuppression was also similar among the groups. However, the trough level of tacrolimus needed for maintenance of an acceptable liver function test during the chronic phase tended to be lower in well-matched pairs, and a high percentage of immunosuppressant-free patients were found in the 0-mismatch group. Fatal graft-versus-host disease developed in one patient with a complete one-way HLA-matched transplant.

CONCLUSION

We could not find any supportive evidence of beneficial effects of HLA-matching in pediatric LRLT. The potential benefit of HLA-matching for the reduction protocol for immunosuppressants may play a role in the withdrawal program. It appears unnecessary to pay attention to HLA compatibility in donor selection in LRLT, except for one-way HLA matching, or to adjust immunosuppression according to HLA compatibility.

Short-term changes in lipid and protein metabolism in liver transplants from living-related donors

The effects of liver transplantation involving living-related donors were investigated in 20 pediatric cases in terms of protein and lipid metabolism using the extent of cholesterol esterification and the levels of total cholesterol, lecithine-cholesterol acyltransferase, apolipoprotein A-I, cholinesterase, and rapid turnover proteins as parameters. Cholesterol esterification increased from preoperative values of 39% +/- 4% to 67% +/- 1% (mean +/- SEM, n = 17) at 3 weeks after liver transplantation in successful cases but decreased from the preoperative value of 45% +/- 10% to 26% +/- 6% (n = 3) at 3 weeks in unsuccessful cases. Cholinesterase, transferrin, and prealbumin levels remained low after 3 weeks even in successful cases. Patients who had partial liver transplantations from living-related donors showed rapid recovery of cholesterol esterification. However, patients with graft livers required an extensive period before normalization of protein metabolism occurred, indicating the necessity for long-term follow-up of recipient development.

An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors

The authors performed 20 liver transplantations from living related donors between June 1990 and July 1991. The 20 pediatric patients (14 biliary atresia, two Budd-Chiari syndrome, one liver cirrhosis after hepatitis C viral infection (HCV hepatitis), 1 progressive intrahepatic cholestasis, 1 liver cirrhosis, 1 protoporphyria) were transplanted with 11 left lobes, eight left lateral segments, and one right lobe. The choice of donors was restricted to the parents of the recipients. The immunosuppressive treatment consisted of FK 506 and steroids. Seventeen recipients are alive, 15 of whom are well and at home. Two recipients, who underwent emergency transplantation, died of postoperative complications. Another recipient died of accidental asphyxia at 6 months after the transplantation. All 20 donors had uneventful postoperative courses and were able to resume their normal social lives. The arterial ketone body ratio (AKBR) increased to above 1.0 within 2 days after the transplantation in all cases. Relatively mild rejection episodes were encountered in only two cases transplanted with ABO-compatible grafts, and these were treated successfully with steroids and FK 506.

The influence of HLA matching on renal allograft survival at a single pediatric center

Between January 1, 1969, and February 2, 1988, 331 pediatric renal transplants were performed at a single pediatric center. Of these 225 were first cadaveric allografts. Graft allocation was independent of the outcome of human lymphocyte antigen (HLA) matching. The results of class I antigen matching were analyzed in 224 transplants, and actuarial graft survivals were calculated. Class II antigen matching was analyzed in 80 patients from January 1, 1982, and submitted to the same analysis. HLA matching could not be demonstrated to be beneficial. It is proposed that any matching benefit is small and obscured in our series by the dominance of other factors.

Does exposure to HLA alloantigens trigger immunoregulatory mechanisms operative in both pregnancy and AIDS?

The complex biological processes responsible for regulating the immune system are presently the subject of considerable interest and study. New insight into this process comes from a variety of observations and it is the purpose of this communication to develop the hypothesis that two seemingly quite disparate observations point to a common biological mechanism bearing on immunoregulation. The observations concern the unique immunologic relationship between mother and fetus and the immunoregulatory abnormalities encountered in HIV-induced acquired immunodeficiency syndrome (AIDS). Exposure to foreign (allo) major histocompatibility complex (MHC) antigens can potentially occur during pregnancy, the transfusion of blood or blood products, or anal insemination. The hypothesis, in its simplest form, states that such MHC alloantigenic exposure triggers a sequence of immunoregulatory mechanisms resulting in immunosuppression and that this response has evolved in placental mammals as a means of protecting the fetus from maternal immune rejection and promoting optimal fetal development.

Blood transfusion in renal transplantation--the induction of tolerance by incompatibility for class I antigen

Blood transfusion given before renal transplantation has been shown to have a powerful immune modulating effect on recipient response to kidney allograft. The mechanism responsible for this effect is still unknown. Here it is assumed that, due to incompatibility for HLA-A related class I antigens between blood donor and recipient, pretransplant blood transfusion may allospecifically induce in the recipient the generation of T cells that have a suppressive effect on T lymphocyte response to incompatible HLA class II antigens present on kidney allograft. Although in many respects this interpretation is still speculative, it is in accord with findings reported from clinical and experimental studies of the effect on graft survival of blood transfusion, both random and donor specific.

Renal transplantation in children

The application of the principles underlying successful renal transplantation in children has led us to increasing success in achieving our goals, which involve more than simple renal function replacement and include effective growth in stature, skeletal and central nervous system development, as well as social development. To succeed in these diverse areas, all modalities of therapy for ESRD may be needed at various times in some patients. Pretransplant therapy must be judiciously selected, and post-transplant protocols often modified to reflect individualized needs.